How We Got Here: The 2023 Ban
In September 2023, the FDA moved 17 peptides to the Category 2 bulk drug substances list — effectively prohibiting licensed compounding pharmacies from producing them for human use.
The peptides affected included household names in the wellness and recovery world: BPC-157, TB-500, KPV, CJC-1295, Ipamorelin, GHK-Cu, Thymosin Alpha-1, and others. The FDA's stated rationale centered on three concerns:
- Impurity risk — peptide manufacturing produces byproducts that are difficult to characterize and control
- Immunogenicity — potential for immune reactions, especially with injectable peptides
- Lack of human safety data — most evidence came from animal studies, not clinical trials
For patients and clinicians who had been using these compounds through compounding pharmacies under physician supervision, the impact was immediate. Legal access through regulated channels shut down. Demand didn't go away — it just moved.
What Happened Next: The Gray Market Problem
When the 2023 restrictions hit, patients didn't stop wanting peptides. What changed was the supply chain. Compounding pharmacies — regulated, inspected, operating under USP sterile standards — could no longer fill prescriptions. In their place, a gray market expanded rapidly: websites selling peptides labeled "for research use only," overseas suppliers, and unverified sources operating outside any regulatory framework.
This is the irony the FDA's critics point to most: removing peptides from the regulated pathway didn't reduce their use — it made the actual supply less safe. Independent testing of gray-market peptides has found incorrect concentrations, contamination with endotoxins, and purity levels as low as 5–75%. The regulated system existed to prevent exactly those problems.
The 2026 Shift: What's Actually Happening
Regulatory Timeline
September 2023 — FDA moves 17 peptides to Category 2, shutting down compounding access.
February 27, 2026 — HHS Secretary RFK Jr. announces approximately 14 of 19 restricted peptides to move back toward legal compounding status. Argues original classifications lacked adequate safety signals.
April 17, 2026 — FDA formally schedules PCAC review meetings for July 23–24, 2026 covering seven specific peptides.
July 23–24, 2026 — PCAC meetings. Day 1: BPC-157, KPV, TB-500, MOTS-C. Day 2: Emideltide (DSIP), Semax, Epitalon.
Late 2026 (earliest) — FDA final determination. Legal compounding access could reopen for approved compounds.
What "Category 1" Actually Means (And What It Doesn't)
This is where most coverage gets sloppy. Category 1 means a substance has adequate safety and usage data and can be compounded by a licensed pharmacy with a valid prescription. It is not FDA approval. The peptide has not gone through an NDA. It cannot be marketed as a drug or sold over the counter.
Think of it as two gates:
Get off Category 2
Remove the restriction that prohibits compounding. This requires PCAC review and FDA determination.
Happening now (July 2026)Get added to 503A bulks list
Formal authorization to compound. This is what actually reopens the legal prescription pathway.
Post-PCAC (Late 2026)As of today, BPC-157 and TB-500 are still Category 2. They are not yet legal to compound. The PCAC meetings in July will be the next formal step toward reclassification.
What This Means for Consumers
Right now: Nothing has changed legally. BPC-157, TB-500, KPV, and the other peptides under review are still restricted from compounding. Gray-market products remain unregulated and legally ambiguous.
After PCAC review (July 2026 at earliest): If the committee recommends reclassification and the FDA issues a final determination, these peptides could become available through licensed compounding pharmacies with a physician's prescription — a legitimate, regulated pathway with quality controls and oversight.
What to avoid in the meantime: Gray-market vendors using "not for human consumption" or "research use only" labels are not a legal safe harbor. The FDA's Intended Use Doctrine looks past labels at how a product is marketed. If a site provides dosing guidance or healing testimonials, the "research only" label offers no legal protection to the buyer or the seller.
What This Means for Clinicians
Do not resume compounding prescriptions yet. BPC-157, TB-500, and related peptides remain Category 2 pending the July PCAC meetings. Prescribing compounded versions now still carries legal and licensing risk. Several states — including Ohio and Florida — have moved to suspend licenses for the presence of research-labeled peptide vials in clinic settings, regardless of patient harm.
Document patient interest now. The pipeline is opening. Being prepared with protocols, informed consent frameworks, and sourcing relationships with licensed 503A pharmacies positions you well for when the regulatory window reopens.
Watch July 23–24. Those PCAC meetings will be the clearest signal yet about which peptides are heading back to legal status and on what timeline.
The Peptide-by-Peptide Breakdown
| Peptide | Current Status | PCAC Meeting | Direction |
|---|---|---|---|
| BPC-157 | Category 2 | July 23, 2026 | Expected → Cat. 1 |
| TB-500 | Category 2 | July 23, 2026 | Expected → Cat. 1 |
| KPV | Category 2 | July 23, 2026 | Expected → Cat. 1 |
| MOTS-C | Category 2 | July 23, 2026 | Expected → Cat. 1 |
| GHK-Cu | Category 2 | Not yet scheduled | Expected → Cat. 1 |
| CJC-1295 | Category 2 | Under review | Pending |
| Ipamorelin | Category 2 | Under review | Pending |
| Thymosin Alpha-1 | Category 2 | Under review | Pending |
| Semaglutide (compounded) | Prohibited | N/A | No change expected |
"Expected → Category 1" reflects announced direction from HHS. No formal FDA rule change has been published as of April 2026.
The Bigger Picture
Peptides represent one of the fastest-growing areas in both clinical medicine and consumer wellness. Insulin is a peptide. So is oxytocin. So is semaglutide — the active ingredient in Ozempic. The regulatory friction around BPC-157 and TB-500 isn't about whether peptides belong in medicine. It's about which ones have the right data to support their clinical use.
The argument from clinicians and compounding advocates isn't that safety doesn't matter. It's that banning regulated compounding — which produced peptides under sterile, inspected, quality-controlled conditions — while doing nothing about the gray market that replaced it, made the risk calculation worse, not better. The current FDA review process suggests that argument is being heard.
What to Watch
- July 23–24, 2026 — PCAC meetings on BPC-157, TB-500, KPV, MOTS-C, Emideltide, Semax, Epitalon
- Post-PCAC — FDA issues final determination on whether each peptide moves to the 503A bulks list
- Ongoing — Additional peptides (GHK-Cu, Dihexa, PE-22-28) expected to be referred to PCAC before end of 2026
Frequently Asked Questions
Not for compounding. It remains Category 2 as of April 2026. PCAC review is scheduled for July 23, 2026. No formal rule change has been published.
Gray-market vendors exist, but products sold "for research use only" are not regulated for human use. Quality, purity, and safety are unverified. The legal pathway through compounding pharmacies is not yet open for these specific peptides.
The earliest realistic timeline is late 2026, following PCAC review in July and FDA final determination. Some peptides may move faster than others.
No. Moving to Category 1 means a peptide can be compounded with a prescription. It is not the same as FDA drug approval, which requires a full NDA process.
Stay informed, document patient demand, build relationships with licensed 503A compounding pharmacies, and wait for the formal regulatory green light before resuming prescriptions. The pathway is opening — act on the legal timeline, not the anticipated one.